NCT04142619View on ClinicalTrials.gov

Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

PHASE1TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 21, 2019

Primary Completion Date

June 18, 2023

Study Completion Date

June 18, 2023

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
BIOLOGICAL

UCARTCS1A

Allogenic engineered T-cells expressing anti- CS1 Chimeric Antigen Receptor

Trial Locations (8)

30322

Winship Cancer Institute Emory University, Atlanta

55905

Mayo Clinical Cancer Center (MCCC), Rochester

77030

MD Anderson Cancer Center, Houston

80218

Sarah Cannon Research Institute - Colorado Blood Cancer Institute, Denver

94115

UCSF Medical Center- Helen Diller Family Comprehensive Cancer Center, San Francisco

07601

Hackensack Meridian Health, Hackensack

37203-1625

Sarah Cannon Research Institute - Tennessee Oncology, Nashville

78229-6306

Sarah Cannon Research Institute - Methodist Healthcare, San Antonio

Sponsors

Lead Sponsor

Cellectis S.A.
All Listed Sponsors
lead

Cellectis S.A.

INDUSTRY